TEMPEST THERAPEUTICS INC

TPST stock represents shares of Tempest Therapeutics, Inc., a clinical-stage biotechnology company. The ticker TPST trades on the Nasdaq Capital Market. Because the company focuses on developing oncology therapies rather than selling commercial products, its stock is often driven by clinical trial progress, regulatory updates, and financing activities rather than routine product revenue.

TPST operates in the biotechnology industry, specifically within the healthcare sector. The company is focused on discovering and developing immune-modulating therapeutics for cancer treatment. As a clinical-stage biotech, its business model centers on research and development, meaning industry-specific risks include trial outcomes, regulatory approvals, and access to capital.

Recent performance for TPST can be tracked using the latest price, daily change, and volume shown on this page. Performance over weeks or months may vary widely because clinical-stage biotech shares often react sharply to study results, financing news, or broader market sentiment. For the most current TPST performance data, refer to the latest figures displayed here.

TPST may experience significant price volatility because it is a clinical-stage biotechnology company. Shares of such companies can move sharply on trial data, regulatory developments, financing announcements, and changes in investor risk appetite. Liquidity and trading volume can also influence volatility. Historical price swings should be reviewed alongside the latest market data shown on this page.

Valuing TPST is challenging because clinical-stage biotech companies often have little or no product revenue, so traditional metrics like the P/E ratio may not apply. Investors may assess cash resources, research pipeline potential, partnership prospects, and share count. The latest TPST valuation-related figures, including market capitalization if shown, should be checked on this page.

Key risks for TPST include clinical trial failure, regulatory delays, limited or no commercial revenue, and the need for additional capital, which can dilute existing shareholders. Competition, intellectual property challenges, and broader market or biotech sector downturns can also pressure the stock. Because TPST is a clinical-stage company, its prospects depend heavily on successful drug development.